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==========

Sorafenib single agent continues to be the only U.S. Food and Drug Administration‐approved systemic therapy for hepatocellular carcinoma (HCC) in 2017 since its approval almost 10 years ago. This study showed that the combination of sorafenib and capecitabine in patients with advanced HCC is an active and safe palliative regimen. The disease response rate observed in this study was higher than the outcomes reported by other studies using sorafenib as single agent \[[1](#onco12200-bib-0001){ref-type="ref"}\], \[[2](#onco12200-bib-0002){ref-type="ref"}\]. The small sample size did not allow determining if this observation translated into a better survival outcome as compared with single‐agent sorafenib. Such a determination will require a randomized phase II trial.

Oral capecitabine has been used as single agent in hepato‐biliary cancers, with a median overall survival of 10 months in patients with HCC and well tolerated in cirrhotic patients \[[3](#onco12200-bib-0003){ref-type="ref"}\]. Other investigators have explored different combinations with capecitabine, including platinum‐based agents and other biological agents targeting vascular endothelial growth factor (VEGF) \[[4](#onco12200-bib-0004){ref-type="ref"}\], \[[5](#onco12200-bib-0005){ref-type="ref"}\], \[[6](#onco12200-bib-0006){ref-type="ref"}\]. All of these studies have shown comparable results with similar treatment toxicity profile.

![Kaplan‐Meier estimate of OS.\
Abbreviations: CI, confidence interval; OS, overall survival.](onco12200-fig-0001){#onco12200-fig-0001}

Similar to data reported in previous studies \[[1](#onco12200-bib-0001){ref-type="ref"}\], \[[2](#onco12200-bib-0002){ref-type="ref"}\], \[[7](#onco12200-bib-0007){ref-type="ref"}\], 46% of our patients had been pretreated with locoregional treatments. Transarterial chemoembolization was the most commonly used locoregional modality prior to the beginning of systemic therapy in our population; this observation is consistent with data previously reported by other investigators and the current standard of care guidelines for the management of intermediate‐stage, unresectable, and multifocal HCC \[[2](#onco12200-bib-0002){ref-type="ref"}\], \[[8](#onco12200-bib-0008){ref-type="ref"}\], \[[9](#onco12200-bib-0009){ref-type="ref"}\].

There were two exceptional responders in this study: one patient had a complete response that lasted 14 months, and another patient had a very good partial response for a duration of 11 months; this patient died of complications from cirrhosis while his cancer was still under good control.

The observed rate of serious adverse events was similar to the results from other studies, supporting the published data regarding the safety of sorafenib in Child‐Pugh B patients \[[7](#onco12200-bib-0007){ref-type="ref"}\], \[[10](#onco12200-bib-0010){ref-type="ref"}\], \[[11](#onco12200-bib-0011){ref-type="ref"}\], \[[12](#onco12200-bib-0012){ref-type="ref"}\]. Moreover, the addition of capecitabine, with dose adjustment as tolerated, did not seem to increase the rate of serious adverse events; there were no treatment‐related deaths, and dosage adjustments were performed as necessary (Table [1](#onco12200-tbl-0001){ref-type="table"}).

###### Treatment tolerance by dose levels

![](onco12200-tbl-0001){#nlm-graphic-5}

Trial Information {#onco12200-sec-0006}
=================

**Disease**Hepatocellular carcinoma**Stage of Disease/Treatment**Metastatic/advanced**Prior Therapy**No designated number of regimens**Type of Study -- 1**Phase II**Type of Study -- 2**Single arm**Primary Endpoint**Safety**Primary Endpoint**Tolerability**Secondary Endpoint**Overall response rate**Secondary Endpoint**Disease control rate**Additional Details of Endpoints or Study Design** The primary analyses for study endpoints were descriptive, and thus the sample size was not based on power analysis or precision level of estimate, but based on empirical considerations according to historical studies. **Investigator\'s Analysis**Active and should be pursued further

Drug Information for Phase II Study {#onco12200-sec-0007}
===================================

Drug 1 Generic/Working nameCapecitabineTrade nameXelodaCompany nameGenentechDrug typeSmall moleculeDrug classAntimetaboliteDose500--850 milligrams (mg) per square meter (m^2^)RouteOral (p.o.)Schedule of administrationCapecitabine and sorafenib were administered b.i.d., 2 weeks on and 2 weeks offDrug 2 Generic/Working nameSorafenibTrade nameNexavarCompany nameBayer and Onyx PharmaceuticalsDrug typeSmall moleculeDrug classMulti‐targeted kinase inhibitorDose200--400 mg per flat doseRouteOral (p.o.)Schedule of administrationCapecitabine and sorafenib were administered b.i.d., 2 weeks on and 2 weeks off

Patient Characteristics for Phase II Study {#onco12200-sec-0010}
==========================================

**Number of Patients, Male**65**Number of Patients, Female**3**Stage**Not collected**Age**Median (range): 65 (58--80)**Number of Prior Systemic Therapies**Median (range): 0 (0--2)**Performance Status: ECOG**0---7 1---5 2---1 3--- Unknown---**Other**Complete baseline demographic and disease characteristics are presented in Table 2.

Primary Assessment Method for Phase II Study {#onco12200-sec-0011}
============================================

Assessment47Number of patients screened47Number of patients enrolled15Number of patients evaluable for toxicity13Number of patients evaluated for efficacy13Evaluation methodResponse evaluation criteria in solid tumors (RECIST) 1.0Response assessment CR*n* = 1 (8%)Response assessment PR*n* = 1 (8%)Response assessment SD*n* = 8 (61%)(Median) duration assessments OS12.7 months, CI: 8.5--23.4

Adverse Events: Phase II Study {#onco12200-sec-0013}
==============================

imageJohn Wiley & Sons, Ltd.[^2][^3]

Assessment, Analysis, and Discussion {#onco12200-sec-0015}
====================================

CompletionStudy terminated before completionTerminated ReasonDid not fully accrueInvestigator\'s AssessmentActive and should be pursued further

 {#onco12200-sec-0016}

This study showed that the combination of sorafenib and capecitabine in patients with advanced hepatocellular carcinoma (HCC) is an active and safe palliative regimen. The disease response rate observed in this study was higher than the outcomes reported by other studies using sorafenib as single agent \[[1](#onco12200-bib-0001){ref-type="ref"}\], \[[2](#onco12200-bib-0002){ref-type="ref"}\]. The small sample size did not allow determining if this observation translated into a better survival outcome as compared with single‐agent sorafenib. Such a determination will require a randomized phase II trial.

Oral capecitabine has been used as single agent in hepato‐biliary cancers, with a median overall survival of 10 months in patients with HCC and well tolerated in cirrhotic patients \[[3](#onco12200-bib-0003){ref-type="ref"}\]. Other investigators have explored different combinations with capecitabine, including platinum‐based agents and other biological agents targeting vascular endothelial growth factor \[[4](#onco12200-bib-0004){ref-type="ref"}\], \[[5](#onco12200-bib-0005){ref-type="ref"}\], \[[6](#onco12200-bib-0006){ref-type="ref"}\]. All of these studies have shown comparable results with similar treatment toxicity profile.

Similar to data reported in previous studies \[[1](#onco12200-bib-0001){ref-type="ref"}\], \[[2](#onco12200-bib-0002){ref-type="ref"}\], \[[7](#onco12200-bib-0007){ref-type="ref"}\], 46% of our patients had been pretreated with locoregional treatments. Trans‐arterial chemoembolization (TACE) was the most commonly used locoregional modality prior to the beginning of systemic therapy in our population; this observation is consistent with data previously reported by other investigators and the current standard of care guidelines for the management of intermediate‐stage, unresectable, and multifocal HCC \[[2](#onco12200-bib-0002){ref-type="ref"}\], \[[8](#onco12200-bib-0008){ref-type="ref"}\], \[[9](#onco12200-bib-0009){ref-type="ref"}\].

One patient had a prolonged complete response (CR) observed during the first 14 months since the beginning of the study regimen. The CR lasted for 11 months before disease progression (Figs. [2](#onco12200-fig-0002){ref-type="fig"}A, [2](#onco12200-fig-0002){ref-type="fig"}B, 3). Another patient on this trial experienced a good partial response and improvement in tumor markers; however, this patient experienced worsening cirrhosis and died of complications of liver cirrhosis (Figs. [4](#onco12200-fig-0004){ref-type="fig"}A, [4](#onco12200-fig-0004){ref-type="fig"}B, 5).

Of note, this study population had a higher proportion of Child‐Pugh class B; (B‐7) patients compared with other studies (46% vs. 5% and 28% in the SHARP trial and GIDEON study, respectively), and similar prevalence of viral hepatitis infection and alcohol use in the HCC populations from North America analyzed in those same studies. The observed rate of serious adverse events was similar to the results from other studies, supporting the published data regarding the safety of sorafenib in Child‐Pugh B patients \[[7](#onco12200-bib-0007){ref-type="ref"}\], \[[10](#onco12200-bib-0010){ref-type="ref"}\], \[[11](#onco12200-bib-0011){ref-type="ref"}\], \[[12](#onco12200-bib-0012){ref-type="ref"}\]. Moreover, the addition of capecitabine, with dose adjustment as tolerated, did not seem to increase the rate of serious adverse events.

Our study represents the first trial combining sorafenib and capecitabine in the management of advanced, unresectable HCC with findings supporting the activity and safety of this regimen. The small sample size does not allow comparison with single‐agent sorafenib or capecitabine and/or in combination with other systemic treatments. Additional phase III data and studies of a larger scale will be necessary to determine if the combination of these two active agents might result in better survival outcomes when compared with the current standard of care.

Figures and Tables {#onco12200-sec-4405}
==================

![Patient 1. Pre‐treatment **(A)** and post‐treatment **(B)** computed tomography scan with a complete response.](onco12200-fig-0002){#onco12200-fig-0002}

![Corresponding alphafeto‐protein (AFP) curve for patient 1. Corresponding to pre‐treatment (Fig. 2A) and post‐treatment (Fig. 2B) computed tomography scan with a complete response.\
Abbreviation: AFP, alphafeto‐protein.](onco12200-fig-0003){#onco12200-fig-0003}

![Patient 2. Pre‐treatment **(A)** and post‐treatment **(B)** partial response on computed tomography scan.](onco12200-fig-0004){#onco12200-fig-0004}

![Corresponding AFP curve for patient 2. Corresponding to pre‐treatment (Fig. 4A) and post‐treatment (Fig. 4B) partial response on computed tomography scan.\
Abbreviation: AFP, alphafeto‐protein.](onco12200-fig-0005){#onco12200-fig-0005}

###### Baseline demographic and disease characteristics

![](onco12200-tbl-0003){#nlm-graphic-25}

Abbreviations: AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; INR, international normalized ratio; TACE, trans‐areterial chemoembolization; TNM, TNM classification of malignant tumors.
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